Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rivaroxaban ACS Specialist Cohort Event Monitoring Study (ROSE ACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02673437
Recruitment Status : Completed
First Posted : February 3, 2016
Last Update Posted : April 24, 2019
Sponsor:
Information provided by (Responsible Party):
Drug Safety Research Unit, Southampton, UK

Brief Summary:
Rivaroxaban is a medicine which reduces the formation of blood clots. Acute coronary syndrome (ACS) comprises a range of disorders, including heart attack and unstable angina, caused by a sudden reduction in blood flow to part of the heart muscle. This study aims to collect information on the use of rivaroxaban and its safety when used by patients for the prevention of atherothrombotic (plaque rupture leading to a blood clot) events following ACS, during the first three months after starting. This study was requested by the European regulatory body (EMA) which is responsible for the use and safety of medicines. It will last for approximately 3 years and is a national study covering the whole of England and Wales. The study aims to recruit 1193 patients who have been prescribed rivaroxaban and antiplatelet therapy and 1193 patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS. Each patient will only be monitored for the first 13 weeks after hospital admission for ACS. Patients who choose to take part will complete a consent form. The patient's care team will be asked to complete a baseline questionnaire about the patient at the time the medicine is given and a further questionnaire up to 16 weeks later, specifically asking about the patient's experiences whilst on the medication. If anything unusual is reported during the observation period, the care team may be asked to fill out a followup questionnaire. With the patient's consent, the study team will also inform the patient's General Practitioner (GP) of their participation in the study and will ask the GP to complete an abridged questionnaire from the patient's medical records. The study team will analyse and aggregate the data, carefully protecting patient confidentiality, to classify adverse events of interest, in particular bleeding events.

Condition or disease Intervention/treatment
Acute Coronary Syndrome Other: This is a non-interventional study

Layout table for study information
Study Type : Observational
Actual Enrollment : 701 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO®) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales
Study Start Date : September 2015
Actual Primary Completion Date : February 28, 2019
Actual Study Completion Date : February 28, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban

Group/Cohort Intervention/treatment
Rivaroxaban group
Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
Other: This is a non-interventional study
This is a non-interventional study

Alternative dual antiplatelet therapy
Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
Other: This is a non-interventional study
This is a non-interventional study




Primary Outcome Measures :
  1. Cumulative incident risk of major bleeding, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital. [ Time Frame: During 12 weeks after initiation of treatment with rivaroxaban or alternative anticoagulant therapy ]

    Cumulative incident risk of major bleeding according to the Thrombolysis In Myocardial Infarction (TIMI) classification of non-coronary artery bypass grafting (non-CABG) Related Bleeding, occurring in the 12 week observation period, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital.The cumulative incidence will be calculated according to the formula:

    Total number of new cases during 12 week observation period x 100 / Population initially at risk If the observed cumulative incidence from this study falls within the range expected as set by the precision limits of cumulative incidence from clinical trial data, then the null hypothesis (of no difference) will not be rejected.


  2. Rate of major bleeding, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital. [ Time Frame: During 12 weeks after initiation of treatment with rivaroxaban or alternative anticoagulant therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients newly prescribed rivaroxaban in any combination with standard oral antiplatelet therapy or current standard antiplatelet combination therapy (at least dual therapy, but not monotherapy) for secondary prevention in patients after ACS
Criteria

Inclusion criteria:

  • Age 18 years or above
  • Patients newly prescribed rivaroxaban in any combination with standard oral antiplatelet therapy for the indication of secondary prevention in patients after ACS
  • Patients prescribed dual antiplatelet therapy (contextual cohort) for the indication of secondary prevention after ACS
  • Patients have provided signed, informed consent

Exclusion criteria:

  • Patients prescribed with oral anticoagulants including rivaroxaban within 6 months prior to the index date for any indication
  • Patients commenced rivaroxaban between date of market launch (28th October 2014) for the indication of secondary prevention after ACS and study start (18th September 2015)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02673437


Locations
Layout table for location information
United Kingdom
Drug Safety Research Unit (for data collation and analysis only)
Southampton, Hampshire, United Kingdom, SO31 1AA
Drug Safety Research Unit
Southampton, Hampshire, United Kingdom, SO31 1AA
Sponsors and Collaborators
Drug Safety Research Unit, Southampton, UK
Layout table for additonal information
Responsible Party: Drug Safety Research Unit, Southampton, UK
ClinicalTrials.gov Identifier: NCT02673437    
Other Study ID Numbers: ROSE ACS
First Posted: February 3, 2016    Key Record Dates
Last Update Posted: April 24, 2019
Last Verified: April 2019
Keywords provided by Drug Safety Research Unit, Southampton, UK:
Acute coronary syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Coronary Syndrome
Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases